



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Idactamab

Cat. No.:	HY-P99654
CAS No.:	2245205-37-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	ASCT2 (SLC1A5) <sup>[1]</sup>
<b>In Vitro</b>	Idactamab inhibits different heme cancer cell lines with IC <sub>50</sub> of 0.05-65 ng/mL <sup>[1]</sup> . ASCT2 (SLC1A5) is a multi-pass, Na <sup>+</sup> -dependent neutral amino acid transporter that mediates the uptake of amino acids required for tumor growth and progression <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Idactamab improves 3 disseminated Acute Myeloid Leukemia (AML) cell line models: The survival rates of TF1α (high expression of ASCT2), MOLM-13 (low expression of ASCT2) and M.V.411 (high expression of ASCT2) were 0.05 mg/kg, 0.1 mg/kg, and 0.1 mg/kg, respectively <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.

[2]. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13\_Supplement): LB-295-LB-295.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA